Background: Mantle-cell lymphoma (MCL) is characterized by overexpression of the Gl cyclin, cyclin Dl, strongly implicating this cell-cycle regulatory element in MCL pathogenesis. Recently, loss-of-function mutations in cell-cycle negative regulatory elements, including p53 point mutations and deletions of the cyclin-dependent kinase inhibitors (CDKJ) pl5 and pl6 have been described in a subset of MCLs and have been associated with aggressive clinical course, blastic morphology, and extranodal dissemination. The objective of the present study was to analyze two newly identified members of the pl6 (INK4A; MTS1) CDKI family, pl8 and pl9, in MCL. Such analyses have not been previously reported.
Introduction
Mantle-cell lymphoma (MCL) has provided a useful model for the investigation of cell-cycle regulatoryelement mutations in human malignancy. An important regulatory checkpoint in cell proliferation occurs in late Gl phase, where cyclin-dependent kinases are activated by Gl cyclins to drive cells through the 'restriction point' into S phase. This positive regulatory function is in turn regulated by cell-cycle inhibitors, including the tumorsuppressor genes p53, pRb, and the pl6 (INK4A; MTS1) family of cyclin dependent kinase inhibitors (CDKI) [1, 2] . Virtually all cases of MCL are characterized by overexpression of the Gl cyclin, cyclin Dl, most in association with the chromosomal translocation t(ll;14)(ql3;q32) [3] [4] [5] . MCLs with p53 mutations have been associated with blastic morphology and a more aggressive clinical course [6] [7] [8] . Similarly, we have shown that p53 mutations and pl5 and pl6 deletions correlate with blastic morphology and the presence of extranodal disease (M.E. Williams et al., submitted manuscript). It is thus reasonable to postulate that cyclin Dl overexpression coupled with loss-offunction (LOF) mutations in p53 or members of the pl6 family CDKI may contribute to the pathogenesis of MCL, and to the development of blastic morphology, extranodal dissemination of disease, and clinically aggressive disease.
Recently, two new members of the pl6 CDKI family, pl8 and pl9, have been described [9, 10] . The pl8 gene has been localized to chromosome Ip32, a site of deletion in about one quarter of t(ll;14) positive MCLs [9, 11] . The pl9 gene localizes to chromosome 19pl3, which has not been identified as a locus of deletion in MCL [12] . Deletion mutations in these genes appear to be rare in human malignancy [13] . However, to our knowledge they have not been previously investigated in MCL, where a selection advantage may exist for CDKI loss in these cyclin Dl-overexpressing cells. We therefore analyzed pl8 and pl9 deletions and rearrangements by Southern blot in both MCL and in the CD5-positive B-cell neoplasm chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL).
Patients and methods
Genomic DNA from 45 cases of MCL and 15 CLL were analyzed. Southern blot analysis was performed on Eco Rl-digested DNA sequentially hybridized with cDNA probes for the pl8 and pl9 genes (kindly provided by Dr. Yue Xiong). In some cases additional analysis was performed with Bam HI and /findIII DNA digests. Gene rearrangements were detected by the appearance of clonal non-germline bands as compared to placental control DNA, while gene deletion was identified by decreased signal intensity relative to placental control DNA and to germline unrearranged bd-\ probe bands [5] .
Results and discussion
P18 rearrangement was identified in one MCL, while a second case had a pl8 deletion (Figures 1 and 2 ). In contrast, detectable pl5 and pl6 deletion occurred in about 10% of these MCLs (M. E. Williams et al., submitted manuscript). No pl9 deletions or rearrangements were identified in MCL, nor were pl8 or pl9 abnormalities detected in the 15 CLLs studied. One MCL had a pl8 gene rearrangement detectable on multiple enzyme digests (Figure 1 ). This patient was a 77-year-old woman who initially presented with clinical stage IA disease with unilateral jugulodigastric lymphadenopathy. Biopsy confirmed a diagnosis of MCL, blastic morphology, with a diffuse growth pattern and numerous mitotic figures. The neoplastic cells were positive for IgM and IgD, kappa light chains, and CD 5 but negative for CD10. She subsequently developed extensive retroperitoneal lymphadenopathy without apparent extranodal disease and died of progressive disease about two and a half years after diagnosis. DNA analysis from this patient (DNA no. 92-20) had previously shown biallelic immunoglobulin heavy-chain joining gene (JH) and monoallelic kappa light-chain joining gene (JK) rearrangements, rearrangement of the 6c/-1 pHOllc locus (probe provided by Dr. S. Galiegue-Zouitina [14] ), and comigration of rearranged JH and pHOllc bands consistent with the translocationt(ll;14)(ql3;q32)(M. E.Williams etal., submitted manuscript). DNA from this patient also revealed homozygous deletion of the chromosome 9p21 pi 5 and pl6 genes; there was no apparent rearrangement or deletion of pi 9. P53 mutational analysis was not performed in this case. Whether the pl8 rearrangement was associated with gene inactivation, and whether it resulted from a translocation event, could not be determined from these studies. No karyotype was performed on this patient's cells. There was no JH or JK comigration with the rearranged pl8 bands. In addition, one JH rearranged band and the rearranged JK band represent the functional alleles in this IgM/D+, kappa-t-population, while the remaining rearranged JH allele was involved in the apparent t(ll;14) based upon comigration with the rearranged pHOllc locus.
A second MCL for which serial tissue samples were available showed evidence of pl8 deletion (Figure 2 ). This 62-year-old man presented with generalized lymphadenopathy, splenomegaly, and renal failure with evidence of glomerulonephritis. Lymph node biopsy revealed MCL, mantle-zone growth pattern, with a mixture of blastic and nonblastic neoplastic cells and a mitotic rate of 14 per ten high-power fields (hpf). Bone marrow biopsy was positive for lymphoma, but there was no apparent peripheral blood involvement. Renal biopsy showed lymphomatous infiltration and a crescentic immune complex glomerulonephritis. He achieved a partial remission with CHOP chemotherapy, and became dialysis independent. However, he rapidly relapsed and underwent splenectomy.
The spleen and splenic hilar lymph nodes showed blastic MCL with a mitotic rate of 33 per 10 hpf. A mantle-zone growth pattern was no longer present. Renal and marrow biopsies continued to reveal lymphomatous involvement, but the crescentic glomerulonephritis showed healing. He received subsequent combination chemotherapy but eventually developed further progression including a leukemic phase. Southern blot analysis of DNA from the original node biopsy, the spleen, and the perihilar node showed pl8 deletion, most evident in the latter two specimens (Figure 2 ). This may have resulted from a relatively greater proportion of clonal neoplastic cells relative to stromal and reactive cells in the spleen and perisplenic node, as suggested by the greater intensity of rearranged immunoglobulin heavy-chain (JH) genes versus residual germline bands. It is also possible that the pl8 deletion was only present in the blastic subset of cells which were more prevalent in these samples.
Thus, pl8 rearrangement or deletion is a rare event in MCL. These results suggest that pl8 may not be a component of the cytogenetically detected chromosome lp deletion reported in a subset of MCLs [11] . However, the sensitivity of the Southern blot technique is limited for detecting hemizygous or homozygous deletions in mixed cell populations (i.e., neoplastic cells admixed with reactive and stromal cells), and it does not detect inactivating point mutations or inactivation by gene methylation. Such analyses are now in progress, and should shed further light on cell-cycle regulatory components involved in MCL pathogenesis.
